News
Aug 30, 2016
VIDEO – ESC 2016: beneficial effects of allogeneic mesenchymal stem cells in HF patients
Javed Butler Describes the main findings from the Phase IIa CardioCell’s Heart Failure study on the safety and efficacy of intravenous infusion of ischemia-tolerant allogeneic mesenchymal stem cells in patients with non-ischemic cardiomyopathy. Also he outlines the main challenges of cardiovascular therapies in cancer patients. VIEW VIDEO HERE